20201006 Transgene_NEC_BostonGene_Press_Release_final
Category: Press release
Positive clinical results for TG4001 and TG6002 and financial visibility secured until 2022
20200916 Results H1 2020 EN
Transgene Announces Upcoming Investor Meetings
20200909 Next investor events
Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002
20200908 Transgene TG6002 Phase 1 EN
Transgene Receives $22.2 million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals
20200804 Transgene – Partial sale Tasly Shares EN
Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers
CP TG4001+avelumab EN – Vdef-
Transgene and Hypertrust Patient Data Care announce successful go-live of the world’s first blockchain solution for clinical trials of personalized healthcare
20200709 PR Hypertrust Transgene EN
Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models
20200622b – BT-001_AACR poster EN
Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
20200622a – Transgene PR AACR 3 posters
Combined General Meeting of May 27, 2020
20200527 TG AGM 2020